Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.